Related Experiment Videos
Parathyroidectomy in the calcimimetic era.
1Centre for Transplant and Renal Research, Westmead Millennium Institute, Department of Renal Medicine, Westmead Hospital, Westmead, NSW 2145, Australia. g.elder@garvan.unsw.edu.au
Nephrology (Carlton, Vic.)
|October 14, 2005
Summary
Cinacalcet HCl improves key biochemical markers in secondary hyperparathyroidism. However, parathyroidectomy remains crucial for specific high parathyroid hormone (PTH) levels, especially in dialysis patients, necessitating further research on long-term outcomes.
Area of Science:
- Nephrology
- Endocrinology
- Surgical Management of Renal Disease
Background:
- Cinacalcet HCl, a calcimimetic, offers medical therapy for secondary hyperparathyroidism.
- Parathyroidectomy data exists for complications and outcomes, but calcimimetic efficacy on patient-based endpoints is unproven.
- Achieving biochemical targets for secondary hyperparathyroidism is challenging for many dialysis patients.
Purpose of the Study:
- To evaluate the role of parathyroidectomy versus calcimimetic therapy in managing secondary hyperparathyroidism.
- To establish evidence-based guidelines for treatment decisions based on parathyroid hormone (PTH) levels and related complications.
- To highlight the need for prospective studies with hard endpoints.
Main Methods:
- Review of available data on parathyroidectomy complication rates and outcomes.
- Analysis of cinacalcet HCl's effect on calcium, phosphate, calcium-phosphate product, and parathyroid hormone (PTH) levels.
- Proposal of treatment guidelines based on intact PTH (iPTH) levels, serum calcium, phosphate, and bone mineral density.
Main Results:
- Cinacalcet HCl improves calcium, phosphate, calcium-phosphate product, and PTH levels.
- Parathyroidectomy is recommended for averaged iPTH > 85-95 pmol/L despite optimal therapy.
- Parathyroidectomy consideration is advised for iPTH > 50 pmol/L with abnormal calcium/phosphate or bone density loss.
Conclusions:
- Parathyroidectomy remains a preferred option for severe secondary hyperparathyroidism.
- Increased parathyroidectomy rates may occur if proposed management guidelines are adopted.
- Prospective studies are essential to define the evidence-based roles of parathyroidectomy and calcimimetics.